Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Therapeutic Drug Monitoring|June 12, 1999
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasmaS Fogli, R Danesi, F Innocenti, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivoG Bocci, R Danesi, U Benelli, et al.
Journal of Chemotherapy (Florence, Italy)|July 23, 2009
Three-times weekly teicoplanin as outpatient treatment of chronic osteoarticular infectionsC Tascini, E Tagliaferri, A Di Paolo, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 1, 1995
Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in miceF Innocenti, R Danesi, A Di Paolo, et al.
Pharmacological Research|September 1, 1995
Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the proliferation of human colon adenocarcinoma cell linesA di Paolo, G Bocci, F Innocenti, et al.
Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society for Environmental Toxicology and Cancer|January 1, 1994
Dissociation between in vitro cytotoxicity and in vivo cardiotoxicity of two new anthracyclines: 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin and 4'-deoxy-4'-iodo-doxorubicinA Pinna, C Agen, A Di Paolo, et al.
Journal of Chemotherapy (Florence, Italy)|January 26, 2006
Idarubicin and idarubicinol effects on breast cancer multicellular spheroidsP Orlandi, C Barbara, G Bocci, et al.
Minerva Pediatrica|April 14, 2011
Combined thrombolytic therapy for atrial thrombus in a preterm infantV Mondì, A Di Paolo, A Fabiano, et al.
Annali Dell'Istituto Superiore Di Sanita|June 6, 2002
[Effects of socio-environmental factors on neurocognitive performance in premature or low-birth weight preschoolers]F Chiarotti, A M Castignani, M Puopolo, et al.
Clinical Drug Investigation|October 28, 2016
Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy VolunteersSrini Ramanathan, Julie A Di Paolo, Feng Jin, et al.
Pageof 10